Sol-Gel Technologies Ltd. (SLGL): Price and Financial Metrics

Sol-Gel Technologies Ltd. (SLGL)

Today's Latest Price: $11.94 USD

0.01 (0.08%)

Updated Feb 21 4:00pm

Add SLGL to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

SLGL Stock Summary

  • For SLGL, its debt to operating expenses ratio is greater than that reported by merely 0.37% of US equities we're observing.
  • With a year-over-year growth in debt of -100%, Sol-Gel Technologies Ltd's debt growth rate surpasses merely 0% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for SLGL comes in at -593.16% -- higher than that of merely 0.74% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Sol-Gel Technologies Ltd are TLC, ANAB, NVAX, GRTS, and ARDS.
  • SLGL's SEC filings can be seen here. And to visit Sol-Gel Technologies Ltd's official web site, go to
SLGL Daily Price Range
SLGL 52-Week Price Range

SLGL Stock Price Chart More Charts

SLGL Price/Volume Stats

Current price $11.94 52-week high $21.00
Prev. close $11.93 52-week low $6.11
Day low $11.50 Volume 113,869
Day high $12.44 Avg. volume 106,020
50-day MA $12.23 Dividend yield N/A
200-day MA $9.52 Market Cap 243.46M

Sol-Gel Technologies Ltd. (SLGL) Company Bio

Sol-Gel Technologies Ltd., a clinical-stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company’s lead product candidates include VERED that has completed Phase II clinical trials for the treatment of papulopustular rosacea; and TWIN and SIRS-T, which has completed Phase II clinical trials for the treatment of acne vulgaris. It is also involved in the development of generic dermatological candidates; and formulation and pre-clinical development of early stage product candidates for acne and rosacea, and other dermatological indications. The company was founded in 1997 and is based in Ness Ziona, Israel

SLGL Latest News Stream

Event/Time News Detail
Loading, please wait...

SLGL Latest Social Stream

Loading social stream, please wait...

View Full SLGL Social Stream

SLGL Price Returns

1-mo -9.20%
3-mo 50.76%
6-mo 41.97%
1-year 82.01%
3-year N/A
5-year N/A
YTD -30.38%
2019 184.88%
2018 N/A
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6223 seconds.